crizanlizumab
novartis
['solace-kids', 'novartis']
dr. matthew henry presented solace-kids study early results for crizanluzimab in #scd patients age 12-18 with similar safety profile to sustain study and good efficacy to prevent severe vocs. looking forward to see future results of group 2 (kids age 5-12) #eha23 
Director of Pediatric BMT @ClevelandClinic #CleClinicCancer @cleclinickids #CleClinicPedsCancer #ChildhoodCancer #pedcsm #bmtsm Tweets = my own opinion.